These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27488874)

  • 1. Comparison of Clinical Outcomes of
    Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
    Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    Lorusso D; Cirillo F; Mancini M; Spatti GB; Grijuela B; Ditto A; Raspagliesi F
    Oncology; 2013; 85(2):122-7. PubMed ID: 23941904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.
    Rudaitis V; Zvirblis T; Kanopiene D; Janulynaite D; Griskevicius L; Janavicius R
    Int J Gynecol Cancer; 2014 Oct; 24(8):1395-400. PubMed ID: 25248112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
    Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
    Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
    Candido-dos-Reis FJ; Song H; Goode EL; Cunningham JM; Fridley BL; Larson MC; Alsop K; Dicks E; Harrington P; Ramus SJ; de Fazio A; Mitchell G; Fereday S; Bolton KL; Gourley C; Michie C; Karlan B; Lester J; Walsh C; Cass I; Olsson H; Gore M; Benitez JJ; Garcia MJ; Andrulis I; Mulligan AM; Glendon G; Blanco I; Lazaro C; Whittemore AS; McGuire V; Sieh W; Montagna M; Alducci E; Sadetzki S; Chetrit A; Kwong A; Kjaer SK; Jensen A; Høgdall E; Neuhausen S; Nussbaum R; Daly M; Greene MH; Mai PL; Loud JT; Moysich K; Toland AE; Lambrechts D; Ellis S; Frost D; Brenton JD; Tischkowitz M; Easton DF; Antoniou A; Chenevix-Trench G; Gayther SA; Bowtell D; Pharoah PD; ; ;
    Clin Cancer Res; 2015 Feb; 21(3):652-7. PubMed ID: 25398451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    Vencken PM; Reitsma W; Kriege M; Mourits MJ; de Bock GH; de Hullu JA; van Altena AM; Gaarenstroom KN; Vasen HF; Adank MA; Schmidt MK; van Beurden M; Zweemer RP; Rijcken F; Slangen BF; Burger CW; Seynaeve C
    Ann Oncol; 2013 Aug; 24(8):2036-42. PubMed ID: 23543211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
    PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and oncologic outcomes of
    Seo JH; Jeong SY; Kim MS; Kang JH; Paik ES; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    Obstet Gynecol Sci; 2019 Nov; 62(6):411-419. PubMed ID: 31777737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
    Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
    Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
    Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
    PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
    Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.